From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Giftify Inc.: Giftify, Inc. Announces Smart Savings Solution for Popular GLP-1 Diabetes and Weight Loss Medications
CardCash.com to Offer Cost-Effective Solutions for High-Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL / ACCESS Newswire / February 20, 2025 / Giftify, Inc. (NASDAQ:GIFT) (t ...
New weight loss drugs aim to promote muscle growth
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Weight-loss drug Zepbound helped drive Ireland to $76 billion in goods exports to the U.S. last year—a bittersweet reminder of the challenges ahead
Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.
Fat, Not Muscle: Drugmakers in Race for Next Weight-Loss Breakthrough
Swiss drugmaker Roche began a study last year of its experimental drug, RG6237, as a monotherapy in people with high body ...
Ozempic, Wegovy coverage demand adds to employer health-insurance costs
Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...
Employer-Sponsored GLP-1 Coverage Becomes Critical for Talent Retention and Acquisition, New 9amHealth Survey Finds
As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey ...
MarketWatch4d
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The price a stock trades at can drastically impact your overall returns. If you wait for a top growth stock to come down to a ...